Introduction
============

Renal cell carcinoma (RCC) is the most common solid kidney cancer. Due to its high metastatic potential, accurate staging is important to determine the appropriate treatment for a patient^\[^[@B1]^\]^. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is widely applied in detecting malignancy and predicting the prognosis, as well as in staging/restaging, and in therapeutic decision-making and monitoring of tumors^\[^[@B2]^,^[@B3]^\]^. However, the application of FDG-PET in the urinary tract is relatively limited because this tract is the major excretion route for FDG, which may mean that background activity obscures the presence of lesions.

Martinez de Llano et al.^\[^[@B4]^\]^ evaluated the performance of FDG-PET in detecting primary, recurrent, and metastatic RCC, as reported in articles published before October 2004. Their meta-analytic study suggested that FDG-PET can be useful in restaging and detecting metastatic disease, but not in detecting primary disease. All 7 studies included in that meta-analysis used FDG-PET, without integrated computed tomography (CT) scans, for imaging. With the development and wider availability of the hybrid PET/CT system, more recent studies have investigated the use of PET/CT. The integrated CT system, although a low-dose CT, is believed to be an improvement over PET alone, as helical CT is the best method to assess a renal mass^\[^[@B5]^\]^.

In this study, we evaluated the performance of the hybrid PET/CT system with regard to RCC. We performed a meta-analysis to see if integrated PET/CT provided a better tool to assist patients with RCC.

Materials and methods
=====================

Search strategy and study selection
-----------------------------------

We conducted MEDLINE searches using combinations of the following items: (a) positron emission tomography (PET) and ^18^F-FDG or fluorodeoxyglucose; (b) renal cell carcinoma (RCC). The search period was limited to between January 2001 and August 2011. The inclusion criteria were: (a) articles (not abstracts or reviews) whose original language was English; (b) studies that evaluated metastases or primary renal tumors; (c) studies that included a minimum of 12 human patients (no animal models); (d) studies that used dedicated PET (or PET/CT) cameras, not coincidence cameras; (e) patients had undergone PET with ^18^F-FDG without other radiotracers; (f) clear specification of the reference test was provided; (g) data were included on the validity indexes of diagnostic studies, that is, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), or adequate data had been given so that we could calculate these values.

The exclusion criteria were: (a) duplicated studies; (b) studies outdated by later research; (c) articles published before 2001; (d) there was insufficient data to compare cases and controls, or no detailed information was given on the methodology used to obtain the images, the way the images were analyzed (qualitative or quantitative methods), or on the type of quantitative data used; (e) abstracts of presentations or posters displayed at congresses (due to lack of data or inadequate reporting of methodology); (f) studies in which the reference test used was not clearly specified, or was not valid; (g) validation studies of technique; and (h) review studies.

Data extraction and quality assessment
--------------------------------------

Two reviewers independently extracted the relevant data from each article and recorded them on a standardized form. Disagreements were resolved by consensus. Reviewers were not blinded with regard to information about the journal name, the authors, the authors' affiliations, or year of publication, as these precautions have been shown to be unnecessary^\[^[@B6]^\]^. For each study, the following information was noted: (a) year of publication and origin; (b) sample size; (c) age distribution of the study population; (d) reference standard tests; and (e) imaging details, namely imaging system (PET or PET/CT), methods of analysis (qualitative, quantitative, or both), and number of experts interpreting the images. Both reviewers independently assessed the methodological quality of the selected studies.

The criteria list is shown in [Table 1](#T1){ref-type="table"}. We mainly followed the recommendations of the Cochrane Methods Working Group on Systematic Review of Screening and Diagnostic Tests^\[^[@B7]^\]^, with some modifications for this specific review. Internal validity criteria (IV) were scored as positive (adequate methods), negative (inadequate methods, potential bias), or unclear (insufficient information was provided for a specific item). Standard performance of FDG-PET was scored positively when the type of PET camera, the dose of FDG, the time between injection and scanning, and the method of reconstruction were clearly described. External validity criteria (EV) were assessed to evaluate generalizability. EV was scored positively if sufficient information was provided so that we could judge the generalizability of the findings. After the consensus meeting, we decided to score all unclear scores as negative. Agreement between both reviewers was quantified by Cohen's κ^\[^[@B8]^\]^. Quality scores were expressed as a percentage of the maximum score. Subtotals were calculated for internal and external validity, with a maximum possible score of 6 in each case. Table 1Criteria used to assess the methodological quality of the studiesCriteria of validityPositive score**Internal validity**IV1Valid reference testPathology from biopsy or surgeryIV2Blind measurement of FDG-PET without knowledge of reference testMentioned in publicationIV3Blind measurement of reference test without knowledge of FDG-PETMentioned in publicationIV4Avoidance of verification biasAssessment by reference test independent of FDG-PET resultsIV5FDG-PET interpreted independently of all clinical informationMentioned in publicationIV6Prospective studyMentioned in publication**External validity**EV1Spectrum of diseaseAll stage of diseaseEV2Demographic informationAge and sex information givenEV3Inclusion criteriaMentioned in publicationEV4Exclusion criteriaMentioned in publicationEV5Avoidance of selection biasConsecutive series of patientsEV6Standard execution of FDG-PETType of camera, dose of FDG, time interval, reconstruction

Statistical analysis
--------------------

Using the original values provided in the articles, we recalculated the data on the sensitivity, specificity, PPV, and NPV of FDG-PET for detecting both locoregional and distant metastases. We did this to avoid rounding-off effects. For articles that did not present their data according to the TNM classification, the reviewers restaged patients according to the TNM classification if the data presented included sufficient detail^\[^[@B9]^\]^.

Numbers of patients with locoregional metastases and distant metastases were placed in a 2 × 2 table independently by each of the 2 reviewers. If data were available for only a subset of patients, those data were included. Meta-analysis was performed using a weighted averages method with inverse of samples for each study, to pool the sensitivity and specificity for locoregional lymph nodes and distant metastases^\[^[@B10]^\]^. PPV and NPV were not subjected to this analysis because these values depend on prevalence, which is rarely constant across studies included in a systematic review^\[^[@B11]^\]^. Summary estimates of sensitivity and specificity were calculated, with 95% confidence intervals (CIs), for the detection of renal or extra-renal lesion of RCC on a scan or lesion basis by FDG-PET. We used the normal approximation to binomial with correction for overdispersion. The heterogeneity test was performed by I-square values and Q statistics. The significance level was set at *P* \< 0.05.

We calculated Spearman correlation coefficients for the diagnostic tests to confirm whether or not the diagnostic odds ratio (DOR) changed according to the diagnostic threshold and to determine the fit with a symmetrical or asymmetrical curve (sROC, where DOR = LR+/LR− (where LR+=senstivity/1−specificity and LR−=(1−sensitivity)/specificity). The Spearman correlation coefficients were not statistically significant, thus we used the symmetrical ROC. Statistical analyses were executed with the Meta-Disc free software package version 1.4.

Results
=======

Literature search
-----------------

The results of our systematic search of the literature in the MEDLINE database are listed in [Table 2](#T2){ref-type="table"}. The initial search resulted in 249 articles. By limiting the results to articles involving only human subjects and with only English content, 61 articles were excluded. After excluding all review articles (36 articles), we were left with 152 potential articles to include in our analysis. The 152 articles were screened by the 2 investigators by their titles and abstracts to see if the purpose of the studies fitted our aim. Then the full articles remaining were further reviewed by the 2 investigators according to the inclusion and exclusion criteria. That is, the studies that did not fulfill our inclusion criteria were excluded (e.g. dedicated PET camera not used or study did not evaluate primary or metastatic RCC). Similarly, any studies that matched one of the exclusion criteria were also excluded. A final total of 14 articles relevant to the diagnosis of RCC via PET or PET/CT were selected^\[^[@B12]^\]^. Llano et al.'s study was confined to the clear cell subtype of RCC. The details of the 14 articles are listed in [Table 3](#T3){ref-type="table"}. Table 2The search strategies used in the MEDLINE databaseStrategyResults(PET or FDG) and RCC249Human210English188Not review article152 Table 3Characteristics of the studies selected for evaluating the diagnostic performance of FDG-PET or FDG-PET/CT in RCCAuthorYearDesign[^a^](#TF1){ref-type="table-fn"}MaleFemaleAge range (years)Mean age (median) (years)Reference[^b^](#TF2){ref-type="table-fn"}FDGReviewerDurationRamdave et al.^\[^[@B12]^\]^2001R141132--7961px10 mCi2--Chang et al.^\[^[@B13]^\]^2003R7823--7655.6px10 mCi----Miyakita et al.^\[^[@B14]^\]^2002R15430--7257.5Px260--370 MBq--1997.1--1998.3Safaei et al.^\[^[@B15]^\]^2002R28826--6954px, fu15 mCireport1996.2--2000.2Wu et al.^\[^[@B16]^\]^2002[P]{.ul}12646--73/px, fu10 mCi2--3--Aide et al.^\[^[@B17]^\]^2003P322133--8660px, fu2 MBp/kg22000.3--2002.7Jadvar et al.^\[^[@B18]^\]^2003R18742--81/px, fu10--15 mCi2--Majhail et al.^\[^[@B19]^\]^2003R19545--82(63)px8--17.3 mCi2--Kang et al.^\[^[@B20]^\]^2004R491728--7958.8px, fu--11995.5--2002.1Park et al.^\[^[@B21]^\]^2009R471631--76(54)px, fu10 mCi--2004.5--2006.6Nakatani et al.^\[^[@B22]^\]^2009R18645--7863px, fu370 MBq/130 MBq≥22000.8--2008.1Kumar et al.^\[^[@B23]^\]^2010R55822--8856.85px fu370 MBq22006.1--2009.12Llano et al.^\[^[@B24]^\]^2010R421620--7962.8px, fu2.5 MBq/kg21997.3--2005.12Ozulker et al.^\[^[@B25]^\]^2011P81040--8157.4px370--555 MBq22008.12--2010.6[^2][^3]

Methodological quality assessment
---------------------------------

[Table 4](#T4){ref-type="table"} presents the methodological quality of the selected studies as assessed by the criteria listed in [Table 1](#T1){ref-type="table"}. The mean total IV score was 2.4, and the mean total EV score was 4.5. The total percentage score for the combined internal and external validity, expressed as a fraction of the maximum score^\[^[@B12]^\]^, ranged from 41.7% to 83.3%, with a mean of 57.7%. Table 4Quality assessment of the studies selected for evaluating the diagnostic performance of FDG-PET or FDG-PET/CT in RCCStudyYearIVEVTotal IV scoreTotal EV score% of max scoreIV1IV2IV3IV4IV5IV6EV1EV2EV3EV4EV5EV6Ramdave et al.^\[^[@B12]^\]^2001+----+----+++----+2450.0Chang et al.^\[^[@B13]^\]^2002+----+------++----+2341.7Miyakita et al.^\[^[@B14]^\]^2002+----+----+++--+--2450.0Safaei et al.^\[^[@B15]^\]^2002+----+------++--+--2341.7Wu et al.^\[^[@B16]^\]^2002+--------++++----+2450.0Aide et al.^\[^[@B17]^\]^2003+----+--++++--++3566.7Jadvar et al.^\[^[@B18]^\]^2003+----+------+++--+2450.0Majhail et al.^\[^[@B19]^\]^2003++--++--+++----+4466.7Kang et al.^\[^[@B20]^\]^2004+----+----+++--+--2450.0Park et al.^\[^[@B21]^\]^[2009]{.ul}+----+------+++++2558.3Nakatani et al.^\[^[@B22]^\]^2009+----+----++++++2666.7Kumar et al.^\[^[@B23]^\]^2010++--++--++++++4683.3Llano et al.^\[^[@B24]^\]^2010+----+----++++++2666.7Ozulker et al.^\[^[@B25]^\]^2011+----+--++++--+--3458.3[^4] Table 5Parameters of the diagnostic accuracy of the studies selected for evaluating the diagnostic performance of FDG-PET or FDG-PET/CT in RCCMethodSiteStudyYearScanTPFPFNTNSensitivity (%)Specificity (%)PETRenalRamdave et al.^\[^[@B12]^\]^2001171501194100Miyakita et al.^\[^[@B14]^\]^2002196013032--Aide et al.^\[^[@B17]^\]^2003351411644780Kang et al.^\[^[@B20]^\]^200417906260100**Pooled6288**ScanExtra-renalRamdave et al.^\[^[@B12]^\]^20011720015100100Chang et al.^\[^[@B13]^\]^20021591149080Aide et al.^\[^[@B17]^\]^20035310304010093Jadvar et al.^\[^[@B18]^\]^200325151637175Majhail et al.^\[^[@B19]^\]^2003241407367100Kang et al.^\[^[@B20]^\]^2004524606088--Nakatani et al.^\[^[@B22]^\]^200928172458171Llano et al.^\[^[@B24]^\]^2010582937198186**Pooled7990**LesionSafaei et al.^\[^[@B15]^\]^200225152268875Wu et al.^\[^[@B16]^\]^200252400012100100Majhail et al.^\[^[@B19]^\]^20033621012364100**Pooled8491**ScanPET/CTRenalOzulker et al.^\[^[@B25]^\]^20111871824767Extra-renalPark et al.^\[^[@B21]^\]^[2009]{.ul}353052269484Kumar et al.^\[^[@B23]^\]^20101036337309091**Pooled9188**[^5]

The low IV score was due to the fact that none of the articles mentioned whether measurement of the reference test was done without knowledge (i.e. with blinding) of FDG-PET (IV3). Only 2 out of 12 articles mentioned the blindness of the FDG-PET interpretation to the knowledge of the reference test and the clinical information (IV2 and IV5). In addition, only 3 articles mentioned that the study design was prospective (IV6). For any criteria not discussed clearly in the article, the relevant dimensions were scored negatively.

The total EV score was higher for more recent articles. For articles published earlier than 2005, only 1 out of the 9 scored up to 5, whereas only 1 of the articles published after 2008 scored less than 5. The lowest EV score was EV4. Only 1 of the 9 articles published before 2005 mentioned the exclusion criteria. The consecutive selection of patients to avoid selection bias (EV5) was not mentioned in 5 articles, all of which were published before 2004.

Accuracy of FDG-PET
-------------------

### Renal lesion

Four articles evaluated the diagnosis of RCC with renal lesions via FDG-PET. The pooled sensitivity and specificity as well as the sROC curve are shown in [Fig. 1](#F1){ref-type="fig"}. However, Miyakita et al.'s study^\[^[@B14]^\]^ contained zero false-positives and true-negatives, thus it is impossible to include it in sROC curve plotting. For renal lesion detection, the pooled sensitivity was 0.62 (95% CI 0.49--0.74) with high heterogeneity; the chi-square value was 11.71, indicating statistical significance (*P* = 0.0029), and the I-square value was 82.9%. The pooled specificity was 0.88 (95% CI 0.47--1.00), with a non-significant chi-square value of 1.02 (*P* = 0.5992) and an I-square value of 0.0%. Figure 1Summary of the sensitivity and specificity as well as the sROC curve for detecting renal lesions of RCC by FDG-PET.

### Extra-renal lesion

Ten articles used FDG-PET to evaluate extra-renal lesions in RCC. Seven of them evaluated on a scan basis, 2 of them on a lesion basis, and one presented both scan-based and lesion-based results. For the scan-based articles, the pooled sensitivity and specificity were 0.79 (95% CI 0.71--0.86) and 0.90 (95% CI 0.82--0.95), respectively ([Fig. 2](#F2){ref-type="fig"}). Neither of the chi-square scores for the pooled sensitivity and specificity were statistically significant, at 9.00 (*P* = 0.1734) and 7.64 (*P* = 0.2657), respectively. The I-square scores for the pooled sensitivity and specificity were 33.4% and 21.5%, respectively. The 3 studies that evaluated the results on a lesion basis were high in heterogeneity ([Fig. 3](#F3){ref-type="fig"}). The pooled sensitivity was 0.84 (95% CI 0.75--0.91) with a significant chi-square value of 22.22 (*P* \< 0.001) and I-square value of 91%. The pooled specificity was 0.91 (95% CI 0.72--0.99) with a non-significant chi-square value of 4.59 (*P* = 0.1006) and I-square of 56.5%. Figure 2Summary of the sensitivity and specificity as well as the sROC curve for detecting extra-renal lesions of RCC on a scan basis by FDG-PET. Figure 3Summary of the sensitivity and specificity as well as the sROC curve for detecting extra-renal lesions of RCC on a lesion basis by FDG-PET.

Accuracy of FDG-PET/CT
----------------------

### Renal lesion

None of the included articles published before 2011 evaluated primary renal lesions in RCC using FDG-PET/CT. By comparing postoperative pathology, Ozulker et al.^\[^[@B25]^\]^ reported a sensitivity of 46.6%, specificity of 66.6% and accuracy of 50% in 18 cases.

### Extra-renal lesion

Only 2 articles focused on extra-renal lesions in RCC, but the results of these 2 studies demonstrated good consistency ([Fig. 4](#F4){ref-type="fig"}). The pooled sensitivity was 0.91 (95% CI 0.84--0.96), with a non-significant chi-square score of 0.41 (*P* = 0.5237) and an I-square score of 0.0%. The pooled specificity was 0.88 (95% CI 0.77--0.94), with a non-significant chi-square score of 0.73 (*P* = 0.3933) and an I-square score of 0.0%. Figure 4Summary of the sensitivity and specificity for detecting extra-renal lesions of RCC on a scan basis by FDG-PET/CT.

Comparison of performance among different modalities
----------------------------------------------------

We were unable to meta-analyze renal-based data to compare the performance of PET and PET/CT, as only one article focused on the detection of renal lesions by PET/CT. For the detection of extra-renal lesions based on scans, neither sensitivity nor specificity differed significantly between PET and PET/CT.

For articles focusing on the detection of extra-renal lesions by PET, the results were presented either on a scan basis or on a lesion basis. We found no significant differences in the performance of PET scans in detecting extra-renal lesions according to whether the interpretations were scan-based or lesion-based.

Only 2 sets of performance showed significant differences. These were: (a) the sensitivity of PET in scan-based renal lesion detection versus lesion-based extra-renal lesion detection; and (b) the sensitivity of scan-based detection of renal lesions by PET versus the detection of extra-renal lesions by PET/CT.

Discussion
==========

RCC is the most common solid kidney cancer. The primary modality chosen for diagnosing, staging, and detecting a recurrence of RCC is the contrast CT scan, with an overall accuracy ranging from 61% to 91%^\[^[@B26]^\]^. However, differentiating between malignant renal masses and benign masses using morphological imaging remains challenging, as RCCs variously appear in CT scans as isodense, hypodense, or hyperdense^\[^[@B29]^\]^. Magnetic resonance imaging (MRI) is generally reserved for patients for whom CT is contraindicated, such as pregnant women or patients who are allergic to the iodinated contrast medium. Also, it is not so accurate.

FDG-PET is a functional imaging technique used to detect various malignancies via observation of increased glucose uptake and increased rate of glycolysis in neoplastic tissue. The application of FDG-PET in cases of renal cancer was first reported by Wahl et al.^\[^[@B30]^\]^ in 1991. However, the value of FDG-PET in RCC is debated, especially for detecting primary renal tumors^\[^[@B12]^,^[@B17]^,^[@B20]^,^[@B31]^,^[@B32]^\]^. The unfavorable performance of FDG-PET in diagnosing renal tumors may partly be due to the fact that the kidneys are the major excretion route for FDG. This results in high and variable background activity that might obscure the actual lesion. Forced diuresis coupled with parenteral hydration could improve the diagnostic accuracy of FDG-PET in various abdominopelvic malignancies, by enhancing urinary flux^\[^[@B33]^\]^. Aide et al.^\[^[@B17]^\]^ administered 10 mg of furosemide intravenously 30 min before imaging, but those results showed the lowest rates of sensitivity and specificity among the 4 studies that we reviewed that evaluated renal lesions via FDG-PET. Ozulker et al.^\[^[@B25]^\]^ administered diuretics according to the same protocol as that used by Aide et al.^\[^[@B17]^\]^, and obtained no better results, even with a PET/CT system. Kamel et al.^\[^[@B33]^\]^ also found that forced diuresis did not improve the characterization of space-occupying lesions in the kidney. In the study by Kamel et al.^\[^[@B33]^\]^, up to 60% of the post-diuretic kidneys displayed activity higher than the background level, which may have resulted from the physiologic FDG activity at the renal tubular epithelium^\[^[@B34]^,^[@B35]^\]^.

In addition to the interference of background activity, the size and the FDG avidity of the RCC may be partly responsible for the performance of FDG-PET. It is generally accepted that well-visualized tumors are larger than non-visualized ones^\[^[@B17]^,^[@B25]^\]^. Most articles stated that FDG avidity was correlated with GLUT-1 expression and the tumor grading, but some did not specify this^\[^[@B14]^,^[@B17]^,^[@B36]^\]^. To sum up, based on the current limited data, FDG-PET is not favorable for diagnosing primary RCCs, even with the assistance of diuretics. We cannot make a conclusion about FDG-PET/CT in the diagnosis of RCCs because of the limited data.

With regard to the ability of FDG-PET to detect extra-renal RCCs, our analysis showed that the pooled sensitivity and specificity were 0.79 and 0.90 when classification was based on scans, and 0.84 and 0.91 when based on lesions. The area under the curve was 0.89 and 0.93, respectively, both better than that in detecting primary renal lesions. These results show that FDG-PET is better able to detect extra-renal rather than renal RCCs, as extra-renal lesions are not obscured by urinary FDG activity. However, FDG-PET may not localize a small lesion as accurately as a larger one. According to a previous study, the sensitivity of FDG-PET increased from 76% to 92.9% when the lesion size increased from more than 1 cm to 2 cm^\[^[@B19]^\]^. In addition to lesion size, FDG-PET may localize high-grade tumors more efficiently than low-grade ones^\[^[@B23]^,^[@B37]^\]^. These factors would affect the sensitivity of FDG-PET in detecting extra-renal lesions of RCC.

The advancement of hybrid PET/CT imaging has improved the definition of a tumor's anatomical location. For extra-renal lesions, PET/CT greatly improves the pooled sensitivity without compromising the specificity of tumor detection. A study by Kumar et al.^\[^[@B23]^\]^ found that the most common causes of a false-negative result were either microscopic metastasis or high physiologic uptake in the background activity. In contrast, false-positive results were due to infection (tuberculosis and neurocysticercosis). Additional advantages of PET/CT in detecting locoregional recurrence of RCC are noted for patients with conditions that may influence the interpretation of CT scans, such as postoperative scarring, surgical clips, and migration of adjacent normal organs into the renal fossa^\[^[@B21]^\]^. Finally, PET/CT can provide an entire body image in one scan, without posing any risk to renal function or possibly incurring an allergic reaction to contrast agents^\[^[@B37]^\]^.

The current study had some limitations. The small number of articles included and the variable quality among them may weaken the findings of our meta-analysis. The predominantly retrospective nature of the studies, and the exclusion of all non-English articles, may have introduced selection bias. The generalizability of our findings may be limited by the clinical heterogeneity among the samples and the diversity in study designs. The difference in publication dates may also be a potential limiting factor. All but 2 articles investigating PET were published before 2004, whereas all the articles investigating the PET/CT system were published after 2008. The results of studies undertaken in these different time periods could have been affected not only by the upgrading of instruments, but also by advances in diagnosis, interpretation, and referencing systems. We recommend that further studies in this area should be carried out, using as large samples as possible, and prospective, randomized, and controlled research designs.

Conclusion
==========

The FDG-PET and CT systems are both useful for detecting extra-renal metastasis in RCC. For detecting extra-renal lesions, the hybrid PET/CT system non-significantly enhances the sensitivity of PET without compromising the specificity. However, further research is required to investigate the ability of PET/CT to detect renal lesions.
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